146335-71-9

Basic information

• Product Name: 1H-1,2,4-Triazol-3-amine, 5-phenoxy-
• CAS NO: 146335-71-9
• Molecular Formula: C8H8N4O
• Molecular Weight: 176.178
• Mol File: 146335-71-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1H-1,2,4-Triazol-3-amine, 5-phenoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-1,2,4-Triazol-3-amine, 5-phenoxy-(146335-71-9)
• EPA Substance Registry System: 1H-1,2,4-Triazol-3-amine, 5-phenoxy-(146335-71-9)

Safety Data

• Hazardous Substances Data: 146335-71-9(Hazardous Substances Data)

Upstream product

• 1088834-19-8 1-diphenylmethyl-5-phenoxy-1H-1,2,4-triazol-3-amine 
• 79463-77-7 N-cyanodiphenylcarbonimidate 

Downstream Products

• 168211-30-1 5-amino-7-methylsulfanyl-2-phenoxy<1,2,4>triazolo<1,5-a><1,3,5>triazine 

Relevant articles and documents

Diphenylmethyl and tetrahydropyranyl protecting groups in the synthesis of 3-substituted 5-amino- and 5-hydrazino-1,2,4-triazoles

The use of hydrazine as reagent in nucleophilic substitution and reduction in the 1,2,4-triazole series in combination with introduction of labile protecting groups makes it possible to synthesize 5-hydrazino-3-nitro-1H-1,2,4- triazole and 3-chloro-5-hydr

Triazole derivative and pharmaceutical use thereof

An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) STR1 or the following formula (III) STR2 wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

Synthesis of 1,2,4-Triazoles and 1,2,4,6-Tetraazabicyclo[3.3.0]octanes from diphenyl cyanocarbonimidate. Competition between addition of hydrazines to esters or nitriles

The reaction of hydrazine with suitably substituted isoureas gives tetraazabicyclo[3.3.0]octanes. The products obtained in this reaction are extremely susceptible to the nature of the substrate and the reaction conditions, but a suitable combination of th